Trial · NCT04645303
Injection of Hyaluronic Acid Versus Corticosteroid for Treatment of Trigger Finger
NCT04645303, Early phase 1, Unknown, Dubai Health Authority
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Injection of Hyaluronic Acid Versus Corticosteroid for Treatment of Trigger Finger. Trials, record NCT04645303. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04645303
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Injection of Hyaluronic Acid Versus Corticosteroid for Treatment of Trigger Finger
- NCT number
- NCT04645303
- Status
- Unknown
- Phases
- Early phase 1
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Dubai Health Authority
- Conditions
- Trigger Finger
- Interventions
- hyaluronic acid (20 mg/2 mL), Triamcinolone acetonide 10mg/ml
- First posted
- 2020-11-27
- Last updated
- 2020-11-27
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Quinnell trigger finger grading system: | 1 and 3 months post-injection | Change in Quinnell grading overtime within 3 months after injection. Trigger fingers are rated as follows: Grade 0: normal finger movements, Grade 1: uneven finger movements, Grade 2: actively correctable triggering, Grade 3: passively correctable triggering, and Grade 4: locked digit. |
| Secondary | Visual analogue scale (VAS) of pain | 1 and 3 months post-injection | Change in pain Visual analogue scale will be recorded. The patient marks on the 100 mm in length line the point that he/she feels to represent his/her perception of pain at the current state. The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks ( a higher score indicates greater pain intensity). Categorization of none, mild, moderate and severe pain will be also used (none = 0, mild = 1-4, moderate = 5-6, and severe = 7-10). |
| Secondary | Frequency of tender trigger nodules | 1 and 3 months post-injection | Identifying the presence of tender nodules at A1-pulley of the affected finger by palpation |
| Secondary | The Quick Disability of the Arm, Shoulder and Hand score | 1 and 3 months post-injection | Patients will be asked to fill a questionnaire form. It is an 11-item form that assesses the upper limb function on a scale of 1-5, with scores ranging from 11 to 55, with the higher scores representing more disability and worse upper limb function. |
| Secondary | Changes in Grip strength | 1 and 3 months post-injection | Measured by the dynamometer strength test (Jamar grip dynamometer) |
| Secondary | Patient satisfaction with therapy | 1 and 3 months post-injection | Participating patients will be asked to classify their result into 1 of 4 categories: (1) complete resolution of symptoms, (2) improved result, but incomplete resolution of symptoms, not warranting further treatment, (3) partial response, but unsatisfactory, warranting further treatment, and (4) no response. |
| Secondary | Ultrasound evaluation of A1-Pulley | 1 and 3 months post-injection | Detailed ultrasonography evaluation of A1-Pulley. Comparing the A1-Pulley ultrasonographic parameters over 3 months after injection (at the follow-up appointment) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04645303
GET https://conductscience.org/api/trials/v1/NCT04645303/registered